Medopad rebrands to Huma and acquires two companies

  • 21 April 2020
Medopad rebrands to Huma and acquires two companies

UK start-up Medopad has announced it is rebranding to Huma and has acquired two UK AI and wearable technology businesses, BioBeats and TLT.

BioBeats is a London-based company which has created a product called BioBase. The mobile app, paired with biosensors and a wearable device, gathers biometric data (e.g. heart rate variability) and psychometric measures (e.g. mood journaling) to provide users with a personalised wellbeing score, fostering an increased understanding of their mental wellbeing.

The company then uses research and AI to create tailored feedback and insights.

David Plans, BioBeats co-founder and chief executive, said: “We are excited to join Huma to realise our ambition for preventative mental health and wellbeing to people around the world. With Huma’s experience, global partners and innovation capabilities, we look forward to joining the Huma team to help people live longer, fuller lives.”

TLT is a Hertfordshire-based medical technology company that has created a wearable device which provides continuous blood pressure monitoring without the need of a cuff.

The rebranding and acquisition of these two companies will allow Huma to add mental health and cardiovascular support to its remote patient monitoring platform.

As well as rebranding and acquiring two companies, Huma has also announced it has appointed former UK Health Minister, Alan Milburn, to chairman of its board of directors.

Huma had a busy year in 2019, raising £19m in fresh funding to fuel digital biomarker studies as well as signing a three-year deal with The Royal Wolverhampton NHS Trust (RWT) to deliver a remote patient management solution.

Dan Vahdat, founder and chief executive of Huma, said: “We’ve been through quite a journey since Medopad started in 2011. Medopad has specialised in remote patient monitoring for patients with rare and chronic diseases.

“Over time, we’ve realised that health is about more than disease states; it’s about general physical and mental wellbeing go hand-in-hand.

“That’s why it makes perfect sense for us to evolve what the company stands for, what we offer, and why we do what we do. That’s why from today, Medopad is now Huma. Huma reflects our commitment to working with people, for people. The name Huma says that we’re for all of humanity.”

Subscribe to our newsletter

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Sign up

Related News

DH Intelligence publishes digital therapeutics market analysis

DH Intelligence publishes digital therapeutics market analysis

Digital Health Intelligence has published its latest market analysis report, where Lloyd Price examines the digital therapeutics market.
Digital Health Coffee Time Briefing ☕

Digital Health Coffee Time Briefing ☕

This briefing features a lawsuit against UnitedHealth and InnoScot Health and Heriot-Watt University partnering for a webinar on medical device compliance.
iPLATO launches medication adherence tool to myGP app

iPLATO launches medication adherence tool to myGP app

iPLATO has launched a new medication adherence tool to its myGP app to help patients follow their medication regimes and improve health outcomes.